<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Suur, M.H.</title>
    <link>http://repub.eur.nl/res/aut/4422/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: A multicenter study in The Netherlands. (Article)</title>
      <link>http://repub.eur.nl/res/pub/3735/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>Abstract
OBJECTIVE: To evaluate the clinical, immunologic, and virologic response to indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 (HIV-1) infection.
STUDY DESIGN: Twenty-eight HIV-1-infected children (3 months to 16 years of age) with or without prior treatment with reverse-transcriptase inhibitors and a HIV-1 RNA &gt;5000 copies/mL and/or a CD4 cell count less than the lower limit of the age-specific reference value were treated with indinavir, zidovudine, and lamivudine. Pharmacokinetics of indinavir were determined in each child.
RESULTS: The combination treatment was well tolerated in the majority of patients. Clinical improvement was seen in all patients. After 6 months of therapy, 70% of the patients had an HIV-1 RNA load below 500 copies/mL, whereas 48% of the children had a viral load below 40 copies/mL. Relative CD4 cell counts in relation to the lower limit of the age-specific reference value increased significantly from a median value of 79% at baseline to 106% after 6 months of therapy. The doses of indinavir necessary to achieve area under the curve values comparable to adult values varied from 1250 mg/m(2)/d to 2450 mg/m(2)/d.
CONCLUSIONS: Highly active antiretroviral therapy consisting of indinavir, zidovudine, and lamivudine in children reduced HIV-1 RNA to less than 500 copies/mL in 70% of the children within 6 months. Improved CD4 cell counts were observed in most patients, as was a better clinical condition (no invasive or opportunistic infections, increased weight gain). Side effects of the triple therapy were mild. Highly active antiretroviral therapy can be used as successfully in children as in adults.</description>
    </item> <item>
      <title>Complement activation in relation to capillary leakage in children with septic shock and purpura (Article)</title>
      <link>http://repub.eur.nl/res/pub/8919/</link>
      <pubDate>1998-01-01T00:00:00Z</pubDate>
      <description>To assess the relationship between capillary leakage and inflammatory
          mediators during sepsis, blood samples were taken on hospital admission,
          as well as 24 and 72 h later, from 52 children (median age, 3.3 years)
          with severe meningococcal sepsis, of whom 38 survived and 14 died.
          Parameters related to cytokines (interleukin 6 [IL-6] IL-8, plasma
          phospholipase A2, and C-reactive protein [CRP]), to neutrophil
          degranulation (elastase and lactoferrin), to complement activation (C3a,
          C3b/c, C4b/c, and C3- and C4-CRP complexes), and to complement regulation
          (functional and inactivated C1 inhibitor and C4BP) were determined. The
          degree of capillary leakage was derived from the amount of plasma infused
          and the severity of disease by assessing the pediatric risk of mortality
          (PRISM) score. Levels of IL-6, IL-8, C3b/c, C3-CRP complexes, and C4BP on
          admission, adjusted for the duration of skin lesions, were significantly
          different in survivors and nonsurvivors (C3b/c levels were on average 2.2
          times higher in nonsurvivors, and C3-CRP levels were 1.9 times higher in
          survivors). Mortality was independently related to the levels of C3b/c and
          C3-CRP complexes. In agreement with this, levels of complement activation
          products correlated well with the PRISM score or capillary leakage. Thus,
          these data show that complement activation in patients with severe
          meningococcal sepsis is associated with a poor outcome and a more severe
          disease course. Further studies should reveal whether complement
          activation may be a target for therapeutical intervention in this disease.</description>
    </item> <item>
      <title>Informed consent, parental awareness, and reasons for participating in a randomised controlled study (Article)</title>
      <link>http://repub.eur.nl/res/pub/8925/</link>
      <pubDate>1998-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: The informed consent procedure plays a central role in
          randomised controlled trials but has only been explored in a few studies
          on children. AIM: To assess the quality of the informed consent process in
          a paediatric setting. METHODS: A questionnaire was sent to parents who
          volunteered their child (230 children) for a randomised, double blind,
          placebo controlled trial of ibuprofen syrup to prevent recurrent febrile
          seizures. RESULTS: 181 (79%) parents responded. On average, 73% of parents
          were aware of the major study characteristics. A few had difficulty
          understanding the information provided. Major factors in parents granting
          approval were the contribution to clinical science (51%) and benefit to
          the child (32%). Sociodemographic status did not influence initial
          participation but west European origin of the father was associated with
          willingness to participate in future trials. 89% of participants felt
          positive about the informed consent procedure; however, 25% stated that
          they felt obliged to participate. Although their reasons for granting
          approval and their evaluation of the informed consent procedure did not
          differ, relatively more were hesitant about participating in future.
          Parents appreciated the investigator being on call 24 hours a day (38%)
          and the extra medical care and information provided (37%) as advantages of
          participation. Disadvantages were mainly the time consuming aspects and
          the work involved (23%). CONCLUSIONS: Parents' understanding of trial
          characteristics might be improved by designing less difficult informed
          consent forms and by the investigator giving extra attention and
          information to non-west European parents. Adequate measures should be
          taken to avoid parents feeling obliged to participate, rather than giving
          true informed consent.</description>
    </item> <item>
      <title>Intrathecal production of interleukin-12 and gamma interferon in patients with bacterial meningitis (Article)</title>
      <link>http://repub.eur.nl/res/pub/8651/</link>
      <pubDate>1997-01-01T00:00:00Z</pubDate>
      <description>To assess the role of interleukin-12 (IL-12) and gamma interferon
          (IFN-gamma) in children with bacterial meningitis, bioactive IL-12 (p70)
          and the inactive subunit p40 and IFN-gamma were measured in serum and
          cerebrospinal fluid (CSF) from 35 children with bacterial meningitis and
          10 control subjects. The production of IFN-gamma is induced by IL-12 with
          tumor necrosis factor alpha (TNF-alpha) as a costimulator and inhibited by
          IL-10. CSF concentrations of IL-12 p40 as well as those of IFN-gamma were
          markedly elevated, whereas IL-12 p70 was hardly detectable. Detectable CSF
          levels of IFN-gamma correlated positively with IL-12 p40 (r = 0.40, P =
          0.02) and TNF-alpha (r = 0.46, P = 0.04) but not with IL-6, IL-8, or
          IL-10. In contrast to CSF levels of TNF-alpha, IL-12, and IL-10, those of
          IFN-gamma were significantly higher in patients with pneumococcal
          meningitis than in children with meningitis caused by Haemophilus
          influenzae and Neisseria meningitidis, presumably because of a high CSF
          TNF-alpha/IL-10 ratio in the former. We suggest that IL-12- and
          TNF-alpha-induced IFN-gamma production may contribute to the natural
          immunity against microorganisms in the CSF compartment during the acute
          phase of bacterial meningitis.</description>
    </item>
  </channel>
</rss>